Cargando…

Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan

BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Quest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattori, Nobutaka, Takeda, Atsushi, Hanya, Yuki, Kitagawa, Tadayuki, Arai, Masaki, Furusawa, Yoshihiko, Mochizuki, Hideki, Nagai, Masahiro, Takahashi, Ryosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/ https://www.ncbi.nlm.nih.gov/pubmed/35077474 http://dx.doi.org/10.1371/journal.pone.0262796

Ejemplares similares

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Validation of an Estonian version of the Parkinson's Disease Questionnaire (PDQ-39)
por: Krikmann, Ülle, et al.
Publicado: (2008)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

Quality of life in patients with Parkinson’s disease: Translation and psychometric evaluation of the Iranian version of PDQ-39
por: Nojomi, Marzieh, et al.
Publicado: (2010)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Spanish version of the Parkinson’s Disease Questionnaire–Carer (PDQ-Carer)
por: Ferrer-Cascales, Rosario, et al.
Publicado: (2016)

Nonmotor-Related Quality of Life in Parkinson's Patients with Subjective Memory Complaints: Comparison with PDQ-39
por: Jenny, Alexis Lionel, et al.
Publicado: (2020)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study
por: Chen, Kui, et al.
Publicado: (2017)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Survey on the Impact of the COVID-19 Pandemic on Patients with Parkinson’s Disease and Their Caregivers in Japan
por: Hattori, Nobutaka, et al.
Publicado: (2023)

Parkinson’s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial
por: Zahra, Mehdi, et al.
Publicado: (2020)

Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson’s disease
por: Dams, Judith, et al.
Publicado: (2013)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino, Carla, et al.
Publicado: (2016)

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
por: Peretz, Chava, et al.
Publicado: (2016)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

PDQ Epidemiology
por: Jekel, James F.
Publicado: (1989)

Biochemistry PDQ
por: Samy, Chander
Publicado: (1987)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease
por: Jiang, Ying, et al.
Publicado: (2017)

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
por: Zhang, Zhenxin, et al.
Publicado: (2018)

PDQ Statistics, Second Edition
por: Chen, Jersey
Publicado: (1998)

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients
por: Barone, P, et al.
Publicado: (2015)

Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

Erratum to: Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
por: Cereda, Emanuele, et al.
Publicado: (2017)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson’s Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study
por: Su, Wen, et al.
Publicado: (2023)

A comparative evaluation of PDQ-Evidence
por: Johansen, Marit, et al.
Publicado: (2018)

Psychometric study of the Persian short-form eight-item Parkinson’s disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL)
por: Fereshtehnejad, Seyed-Mohammad, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2h4ottbvfs0a9qsbmkfbhbgn11